Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Pembrolizumab as First-Line Therapy for Metastatic Non-Small-Cell Lung CancerImmunotherapy, 2017
- Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapyRadiotherapy and Oncology, 2017
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Genetic changes of non-small cell lung cancer under neoadjuvant therapyOncotarget, 2016
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancerAnnals of Oncology, 2014
- The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of SurvivalJournal of Clinical Oncology, 2012
- Representativity of TMA Studies2010